Skip to main content
Signal8

REVELATION BIOSCIENCES, INC. (REVB)

Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Revelation Biosciences, Inc. logo

Revelation Biosciences, Inc.

NASDAQ:REVBHealthcare
AH-3.48%$3.74
Close$3.88+1.57%
Mkt Cap$2.65M
EV-$7.3M
Float539K
O/S683K
VOL13K sh
$ Vol$50K
RVOL0.59×
Inst Own6.1%
SI2.4%
Net Cash/Sh+$14.56
Dilution
Revelation Biosciences, Inc. logoNASDAQ:REVBAH$3.74-3.48%
Financials Summary
Revenue$0
Net Income-$8.91M
Total Assets$11.58M
Free Cash Flow-$8.27M
Debt & Equity
Debt 8%
Equity 92%
Total Debt$747K
Total Equity$8.86M
Shares Outstanding
Short Interest

No short interest data available.

Split History6 splits · 6 reverse
2-year cumulative
1:1,344Over cap

Past the 1:250 Nasdaq cap, ineligible for a bid-price compliance period

  1. 1:7Reverse split
    Oct 20, 20267 shares → 1
  2. 1:4Reverse split
    Jan 28, 20264 shares → 1
  3. 1:3Reverse split
    Jul 7, 20253 shares → 1
  4. 1:16Reverse split
    Jan 28, 202516 shares → 1
  5. 1:30Reverse split
    Jan 25, 202430 shares → 1
  6. 1:35Reverse split
    Feb 1, 202335 shares → 1
Balance Sheet Details
Assets$11.58M
Liabilities$2.72M
Accounts Receivable$0
Accounts Payable$578K
Inventory$0
PP&E (Net)$740K
Goodwill$0
Intangible Assets$0
Income Statement
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
CurrencyUSDUSDUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$0$0$0$0$0$0$0
YoY Growth-------
Cost of Revenue$27K$28K$25K$40K$0$0$0
Gross Profit-$27K-$28K-$25K-$40K$0$0$0
Gross Margin-------
Research and Development$4.06M$3.55M$4.15M$5.38M$6.91M$2.56M$0
Selling, General, and Administrative$5.01M$4.43M$4.51M$5.49M$5.04M$1.23M$4K
Other$0$0$0$0$0$0$0
Total Operating Expenses$9.07M$7.98M$8.66M$10.86M$11.95M$3.8M$4K
Operating Income (EBIT)-$9.07M-$7.98M-$8.66M-$10.86M-$11.95M-$3.8M-$4K
Operating Margin-------
Interest Expense$0$0$0$0$42K$0$0
Interest Income$0$0$0$0$0$11K$0
Other Income (Expense)$157K-$7.06M$8.54M$35K-$36K$126$0
Income Before Tax (EBT)-$8.91M-$15.04M-$120K-$10.83M-$11.99M-$3.8M-$4K
Income Tax Expense$0$0$0$0$0$0$0
Net Income-$8.91M-$15.04M-$120K-$10.83M-$11.99M-$1.63M-$4K
Net Income Margin-------
Supplementary Data
EPS-167.65-613.76-58.87-67503.59-142800.00-63228.83-47.04
Diluted EPS-167.65-613.76-58.87-67503.59-142800.00-63228.83-47.04
Weighted Average OS88,68624,5012,041160842677
EBITDA-$9.04M-$7.95M-$8.63M-$10.84M-$11.93M$0-$4K
EBITDA Margin-------
Balance Sheet
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
CurrencyUSDUSDUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Assets
Current Assets
Cash and Cash Equivalents$10.7M$6.5M$11.99M$5.25M$1.27M$12K$0
Short-Term Investments$0$0$0$0$0$525K$0
Cash and Short-Term Investments$10.7M$6.5M$11.99M$5.25M$1.27M$537K$0
Accounts Receivable$0$0$0$0$0$0$0
Inventory$0$0$0$0$0$0$0
Other Current Assets$34K$50K$101K$73K$149K$0$0
Total Current Assets$10.81M$6.57M$12.15M$5.4M$1.91M$651K$0
Long-Term Assets
Property, Plant & Equipment Net$740K$56K$65K$90K$130K$0$0
Goodwill$0$0$0$0$0$0$0
Intangible Assets$0$0$0$0$0$0$0
Long-Term Investments$0$0$0$0$0$73.51M$0
Deferred Tax Assets$0$0$0$0$0$0$0
Other Long-Term Assets$31K$0$0$0$0$0$23K
Total Long-Term Assets$771K$56K$65K$90K$130K$73.51M$23K
Other Assets$0$0$0$0$0$0$0
Total Assets$11.58M$6.62M$12.21M$5.5M$2.04M$74.16M$23K
Liabilities
Current Liabilities
Accounts Payable$578K$784K$1.36M$554K$596K$0$0
Short-Term Debt$23K$0$0$0$17K$0$0
Current Income Tax Payable$0$0$0$0$0$0$0
Current Unearned Revenue$0$0$0$0$0$0$0
Other Current Liabilities$210K$2K$3.44M$2.91M$0$3.43M$26K
Total Current Liabilities$2M$1.91M$5.56M$4.45M$2.14M$3.43M$26K
Long-Term Liabilities
Long-Term Debt$0$0$0$0$0$0$0
Long-Term Unearned Revenue$0$0$0$0$0$0$0
Long-Term Deferred Tax Liabilities$0$0$0$0$0$0$0
Other Long-Term Liabilities$0$0$0$0$0$2.91M$0
Total Long-Term Liabilities$724K$0$0$0$0$2.91M$0
Other Liabilities$0$0$0$0$0$1$0
Total Liabilities$2.72M$1.91M$5.56M$4.45M$2.14M$6.34M$26K
Stockholders' Equity
Preferred Stock$0$0$0$0$0$0$0
Common Stock$2K$522$265$77$282$73.51M$0
Retained Earnings-$49.42M-$40.51M-$25.47M-$25.35M-$14.52M-$5.69M-$4K
Comprehensive Income & Other$0$0$0$0$0$0$0
Other Stockholders' Equity$58.28M$45.21M$32.11M$26.4M$14.42M$0$0
Total Equity$8.86M$4.71M$6.65M$1.05M-$99K$67.82M-$4K
Minority Interest$0$0$0$0$0$0$0
Total Liabilities and Equity$11.58M$6.62M$12.21M$5.5M$2.04M$74.16M$23K
Supplementary Data
Total Debt$747K$0$0$0$17K$0$0
Net Debt-$9.95M-$6.5M-$11.99M-$5.25M-$1.26M-$12K$0
Cash Flow Statement
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
CurrencyUSDUSDUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating Activities
Net Income-$8.91M-$15.04M-$120K-$10.83M-$11.99M-$1.63M-$4K
Depreciation & Amortization$27K$28K$25K$25K$17K$3.8M$0
Deferred Income Tax$0$0$0$0$0$0$0
Stock-Based Compensation$595K$169K$156K$301K$471K$44K$0
Changes in Working Capital:
  Accounts Receivable$0$0$0$0$0$0$0
  Inventory$0$0$0$0$0$0$0
  Accounts Payable-$206K-$576K$750K-$666K-$270K$0$0
  Other Working Capital$200K-$2.85M$232K-$65K$626K-$80K$4K
Total Working Capital Change-$6K-$3.42M$982K-$731K$356K-$80K$4K
Other Non-Cash Items$28K-$56K-$8.33M$15K$52K-$2.34M$0
Net Cash from Operating-$8.27M-$18.32M-$7.29M-$11.22M-$11.09M-$215K$0
Investing Activities
Capital Expenditures$0-$19K$0$0-$132K$0$0
Acquisitions$0$0$0$0$0$0$0
Purchases of Investments$0$0$0$0$0-$74.04M$0
Sales of Investments$0$0$0$0$525K$0$0
Other Investing Activities$0$0$0$0-$525K$0$0
Net Cash from Investing$0-$19K$0$0-$132K-$74.04M$0
Financing Activities
Debt Repaid-------
Common Stock Issuance$12.47M$12.85M$14.03M$4.45M$600K$74.25M-$10K
Common Stock Repurchases$0$0$0$0$0$0$0
Dividends Paid$0$0$0$0$0$0$0
Other Financing Activities$0$0$34$11.54M$0$0$10K
Net Cash from Financing$12.47M$12.85M$14.03M$15.2M$8M$74.26M$0
Forex Effect$0$0$0$0$0$0$0
Net Change in Cash$4.2M-$5.49M$6.74M$3.98M-$3.22M$12K$0
Supplementary Data
Operating Cash Flow-$8.27M-$18.32M-$7.29M-$11.22M-$11.09M-$215K$0
Capital Expenditure$0-$19K$0$0-$132K$4$0
Free Cash Flow-$8.27M-$18.34M-$7.29M-$11.22M-$11.22M-$215K$0
Cash at Beginning$6.5M$11.99M$5.25M$1.27M$4.49M$0$0
Cash at End$10.7M$6.5M$11.99M$5.25M$1.27M$12K$0